(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024127 A3

(51) International Patent Classification[7]: A61K 31/404, 9/16

(21) International Application Number:
PCT/IB2003/005293

(22) International Filing Date:
10 September 2003 (10.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/421,133 10 September 2002 (10.09.2002) US

(71) Applicant *(for all designated States except US)*: **PHARMACIA ITALIA S.p.A.** [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: **GATTI, Paolo** [IT/IT]; Via Pietro Crisofoli 3/7, I-20014 Genova (IT).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
3 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND

(57) Abstract: The present invention features formulations of indolinones. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an indolinone, and a pharmaceutically acceptable carrier therefor. The formulations and the compounds themselves are useful for the treatment of protein kinase related disorders.

WO 2004/024127 A3